GlassScriptPhysician profile
Luay Shayya
NPI 1104192442
$20,827.19
in general payments reported to CMS, 2019-2025
88 companies · $3,457 in 2025
The $3,457 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $2,065 · 2021: $2,963 · 2022: $3,186 · 2023: $3,956 · 2024: $3,574 · 2025: $3,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $12.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,974.86 |
| Education | $12.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,606.00 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $1,986.57 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Alexion Pharmaceuticals, INC. | $1,152.57 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $1,144.28 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,098.00 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Allergan, INC. | $819.51 | 2019-2022 | |
| Lilly USA, LLC | $784.85 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Pfizer INC. | $766.05 | 2023-2025 | |
| Sk Life Science, INC. | $649.39 | 2020-2025 | |
| Argenx US, INC. | $583.66 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $571.48 | 2019-2023 | Hizentra |
| Amgen INC. | $511.10 | 2019-2024 | Uplizna, Aimovig |
| Mdd US Operations, LLC | $506.30 | 2022-2025 | Apokyn, Apokyn |
| Abbott Laboratories | $442.50 | 2021-2025 | Proclaim, Eterna, Infinity |
| Eisai INC. | $426.88 | 2019-2025 |
Show all 88 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luay Shayya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.